Evidence map›Paper›PMID 36758065›Full record

ArticlePloS one2023

Development and validation of a clinical score for identifying patients with high risk of latent autoimmune adult diabetes (LADA): The LADA primary care-protocol study.

Pilar Vich-Pérez, Juan Carlos Abánades-Herranz, Gustavo Mora-Navarro, Ángela María Carrasco-Sayalero, Miguel Ángel Salinero-Fort, Ignacio Sevilla-Machuca, Mar Sanz-Pascual, Cristina Álvarez Hernández-Cañizares, Carmen de Burgos-Lunar, LADA-PC Research Consortium

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Pilar Vich-PérezInternal Medicine Specialist, Member of the MADIABETES Research Group, Principal Investigator, Los Alpes Health Center, Madrid, Spain.ORCID 0000-0002-6702-909X
Juan Carlos Abánades-HerranzMember of the MADIABETES Research Group, Monóvar Health Center, Madrid, Spain.
Gustavo Mora-NavarroMember of the RedGDPS Foundation, Los Alpes Health Center, Madrid, Spain.ORCID 0000-0002-0604-5205
Ángela María Carrasco-SayaleroSpecialist in Clinical Immunology, Ramon y Cajal University Hospital, Madrid, Spain.
Miguel Ángel Salinero-FortHead of the Knowledge Management Area of the Madrid Health Council, Scientific Director of the MADIABETES Research Group, Madrid, Spain.
Ignacio Sevilla-MachucaLos Alpes Health Center, Madrid, Spain.
Mar Sanz-PascualMember of the MADIABETES Research Group, Aquitania Health Center, Madrid, Spain.
Cristina Álvarez Hernández-CañizaresCanillejas Health Center, Madrid, Spain.
Carmen de Burgos-LunarMember of the MADIABETES Research Group, Specialist in Epidemiology and Public Health, San Carlos Clinical Hospital, Madrid, Spain.
LADA-PC Research Consortium
Madrid Health Service · ESHospital Clínico San Carlos · ESInstituto Cajal · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLatent autoimmune diabetes in adults (LADA) is a type of diabetes mellitus showing overlapping characteristics between type 1 Diabetes Mellitus and type 2 Diabetes Mellitus (T2DM), and autoimmunity against insulin-producing pancreatic cells. For its diagnosis, at least one type of anti-pancreatic islet antibody (GADAb is the most common) is required. Many authors recommend performing this measure in all newly diagnosed patients with DM, but it is not possible in Primary Health Care (PHC) due to its high cost. Currently, a relevant proportion of patients diagnosed as T2DM could be LADA. Confusing LADA with T2DM has clinical and safety implications, given its different therapeutic approach. The main objective of the study is to develop and validate a clinical score for identifying adult patients with DM at high risk of LADA in PHC.

methodsThis is an observational, descriptive, cross-sectional study carried out in Primary Care Health Centers with a centralized laboratory. All people over 30 years of age diagnosed with diabetes within a minimum of 6 months and a maximum of 4 years before the start of the study will be recruited. Individuals will be recruited by consecutive sampling. The study variables will be obtained through clinical interviews, physical examinations, and electronic medical records. The following variables will be recorded: those related to Diabetes Mellitus, sociodemographic, anthropometric, lifestyle habits, laboratory parameters, presence of comorbidities, additional treatments, personal or family autoimmune disorders, self-perceived health status, Fourlanos criteria, and LADA diagnosis (as main variable) according to current criteria. DISCUSSION: The study will provide an effective method for identifying patients at increased risk of LADA and, therefore, candidates for antibody testing. However, a slight participation bias is to be expected. Differences between participants and non-participants will be studied to quantify this potential bias.

Indexed as

Autoimmune DiseasesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Glucose IntoleranceLatent Autoimmune Diabetes in AdultsAdultAutoantibodiesCross-Sectional StudiesHumansObservational Studies as TopicPrimary Health CareAutoantibodies

Identifiers

PMID36758065
PMCPMC9910627
OpenAlexW4319656691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.